# Novo Nordisk A/S clinical trials: 1,411

ClinicalTrials.gov lists 1,411 trials with Novo Nordisk A/S as lead sponsor, 80 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Novo Nordisk A/S: 1,411 rows for $70.55, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,411
- Recruiting or not yet: 80
- Read on: November 19, 2026

## Trials

The 25 newest of 1,411, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944118 | Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944118) |
| November 17, 2026 | NCT07940803 | A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes | Novo Nordisk A/S | Phase 1/2 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes Mellitus | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940803) |
| November 17, 2026 | NCT07940582 | A Research Study Investigating How a New Medicine NNC0721-5186 Works in Women Living With Overweight or Obesity | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940582) |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| November 12, 2026 | NCT07931495 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931495) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| October 28, 2026 | NCT07900438 | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in... | Novo Nordisk A/S | Phase 4 | Recruiting | Cardiovascular Risk, Chronic Kidney Disease | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900438) |
| October 26, 2026 | NCT07896109 | A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes | Novo Nordisk A/S | Phase 1 | Recruiting | Diabetes Mellitus, Type 2 | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896109) |
| October 19, 2026 | NCT07881770 | Semaglutide Health Outcomes and Patient Adherence in Australia | Novo Nordisk A/S | Observational | Not yet recruiting | Overweight, Obesity | 10,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881770) |
| October 9, 2026 | NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868354) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 2, 2026 | NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855133) |
| September 30, 2026 | NCT07850765 | Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets | Novo Nordisk A/S | Observational | Completed | Overweight, Obesity | 1,260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850765) |
| September 29, 2026 | NCT07845578 | A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight | Novo Nordisk A/S | Phase 1 | Recruiting | Obesity, Overweight | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845578) |
| September 21, 2026 | NCT07830732 | A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A | Novo Nordisk A/S | Phase 3 | Recruiting | Haemophilia A | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830732) |
| September 21, 2026 | NCT07829406 | A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People | Novo Nordisk A/S | Phase 1 | Recruiting | Healthy Volunteers | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829406) |
| September 16, 2026 | NCT07822061 | AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight | Novo Nordisk A/S | Phase 3 | Recruiting | Overweight, Obesity | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822061) |
| September 14, 2026 | NCT07817251 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Novo Nordisk A/S | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817251) |
| September 11, 2026 | NCT07815067 | A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815067) |
| September 9, 2026 | NCT07808788 | A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Chronic Kidney Disease | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808788) |
| September 1, 2026 | NCT07797855 | A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy People | Novo Nordisk A/S | Phase 1 | Recruiting | Healthy Volunteers, Cardiometabolic Diseases | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797855) |
| September 1, 2026 | NCT07797335 | AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People... | Novo Nordisk A/S | Phase 3 | Recruiting | Type 2 Diabetes, Cardiovascular Risk | 1,778 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797335) |
| August 24, 2026 | NCT07781371 | A Retrospective Real-World Cohort Study | Novo Nordisk A/S | Observational | Active not recruiting | Obesity, Type 2 Diabetes (T2D), Prediabetes, Cardiovascular Disease (CVD), Dyslipidemia, Metabolic... | 100,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781371) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 467 |
| Phase 1/2 | 2 |
| Phase 2 | 108 |
| Phase 3 | 369 |
| Phase 4 | 105 |
| Not applicable | 3 |
| Observational | 356 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,199 |
| Recruiting | 67 |
| Terminated | 44 |
| Active not recruiting | 38 |
| Enrolling by invitation | 28 |
| Withdrawn | 21 |
| Not yet recruiting | 13 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus | 642 |
| Diabetes Mellitus, Type 2 | 638 |
| Diabetes Mellitus, Type 1 | 225 |
| Obesity | 206 |
| Overweight | 100 |
| Hemophilia A | 68 |
| Nutrition Disorders | 37 |
| Hemophilia B | 36 |
| Renal Insufficiency, Chronic | 29 |
| Dwarfism, Pituitary | 27 |
| Inflammation | 21 |
| Genetic Diseases, Inborn | 19 |
| Arthritis, Rheumatoid | 14 |
| Non-alcoholic Fatty Liver Disease | 12 |
| Turner Syndrome | 12 |
| Heart Failure | 11 |
| Growth Disorders | 8 |
| Noonan Syndrome | 8 |
| Atherosclerosis | 8 |
| Wounds and Injuries | 6 |
| Anemia, Sickle Cell | 6 |
| Neoplasms | 5 |
| Cerebral Hemorrhage | 5 |
| Thalassemia | 5 |
| Thrombasthenia | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [Day care centers in the United States](https://specstream.ai/data/businesses/day-care-centers/united-states)
- [Pakistani restaurants in the United States](https://specstream.ai/data/businesses/pakistani-restaurants/united-states)
- [B2B newspaper advertising companies in the United States](https://specstream.ai/data/businesses/b2b-newspaper-advertising-companies/united-states)
- [Importers in the United States](https://specstream.ai/data/businesses/importers/united-states)
- [Theme restaurants in the United States](https://specstream.ai/data/businesses/theme-restaurants/united-states)
